Events

From Lab to GMP: Industry Leaders Break Down the Operational Realities Behind Scaling Biotech Innovation

At our most recent Insights to Impact event in the Philadelphia Region “From Lab to GMP: Building a Clinical Ready Biotech,” industry leaders pulled back the curtain on one of the least glamorous, but most critical, parts of biotech innovation: operational execution. While scientific breakthroughs often dominate headlines, the conversations throughout the evening made one […]

Featured News

Latest News

From Lab to GMP: Industry Leaders Break Down the Operational Realities Behind Scaling Biotech Innovation

At our most recent Insights to Impact event in the Philadelphia Region “From Lab to GMP: Building a Clinical Ready Biotech,” industry leaders pulled back the curtain on one of the least glamorous, but most critical, parts of biotech innovation: operational execution. While scientific breakthroughs often dominate headlines, the conversations throughout the evening made one […]

Why Sustainability Is a Business Strategy, Not a Nice-to-Have for AstraZeneca

A fireside chat with AstraZeneca’s Dafni Bika at ISPE MAST Showcase made the case that decarbonization, AI, and people-centered leadership are converging into one operating discipline for pharma. When Dafni Bika, Ph.D., started out as a materials scientist and chemical engineer, nobody in her labs said “sustainability.” They called it value engineering — wringing every […]

Jeeva Clinical Trials Acquires Clintelligence AI to Advance Smarter Clinical Development

MANASSAS, Va. —Jeeva Clinical Trials announced the acquisition of Clintelligence AI, an AI-powered protocol intelligence platform designed to improve trial planning, accelerate patient recruitment, and reduce clinical development risk. The acquisition expands Jeeva’s growing AI-ready clinical research infrastructure and strengthens its position as a next-generation platform for decentralized and hybrid clinical trials. The integration of […]

Bora Pharmaceuticals to Acquire MacroGenics Manufacturing Facility in $122.5 Million Deal

ROCKVILLE, Md. — May 13, 2026 — Bora Pharmaceuticals, a Taiwan-based contract development and manufacturing organization (CDMO), has entered into an agreement to acquire MacroGenics’ biologics manufacturing facility and related warehouse operations in Rockville, Maryland, for $122.5 million upfront, with the potential for an additional $5 million tied to future operational milestones. The transaction expands […]

The Other Side of Arcellx’s $7.8 Billion Exit: What the Gilead Buyout Means for Maryland’s Biotech Workforce

When Gilead Sciences announced its $7.8 billion acquisition of Arcellx earlier this year, the deal was largely framed as a strategic win in the escalating race to dominate next-generation CAR-T therapies. The acquisition gives Gilead full control of anito-cel, a late-stage multiple myeloma therapy viewed by many as one of the most promising challengers in […]

In Conversation with Shannon Ryan: Why AI Readiness—not Adoption—is Becoming Biotech’s Real Bottleneck

In life sciences, the conversation around AI has moved quickly from if to how. But beneath that momentum lies a more fundamental question: are organizations actually ready to use it? That gap—between interest and readiness—is becoming one of the defining challenges for the industry. At the upcoming AAPS National Biotechnology Conference, that tension will be […]

In Conversation with Preeyam Patel: The Biomarker Challenge Shaping the Next Era of Drug Development

For much of modern drug development, the question hasn’t just been can we target the biology—it’s been can we prove it early enough to matter. That tension is becoming increasingly visible as therapies grow more precise and biology more complex. At this year’s AAPS National Biotechnology Conference, that challenge is moving to the forefront, with […]

Aldevron and Minaris Renew Lentiviral Plasmid Agreement to Accelerate Cell and Gene Therapy Development

Aldevron, a Danaher company and global leader in the production of DNA, RNA, and proteins for genomic medicine, and Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodal biosafety testing provider, announced the renewal of their lentiviral plasmid licensing agreement designed to expand access to scalable plasmid solutions […]

The Infrastructure Behind Innovation: Why Building Biotech’s Backbone Is Becoming Strategic

In conversation with Heffron’s Matt McGrath on the people and projects enabling innovation to scale In life sciences, the spotlight often falls on discovery—on the science, the therapeutics, the breakthroughs. But behind every lab, cleanroom, and manufacturing suite is a different kind of expertise: the people responsible for building the environments where innovation can actually […]